Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 16, 2012

View Archived Issues

Phase III trial compares antibiotics in children with neglected tropical disease

Study links gene's methylation status to response of colorectal cancer to chemotherapy

Sustained T-cell responses obtained with HCV vaccine based on rare adenoviral vectors

Novel dual specificity protein kinase TTK inhibitors reported

XiberScience identifies new RhoA-inhibiting peptides

Novel PET imaging agent described for use in breast cancer diagnosis

Medivir designs new cathepsin S inhibitors

Stem Cell Educator therapy evaluated in patients with type 1 diabetes

Chinese company patents novel PPAR agonists

Pfizer presents new glucokinase activators

Otsuka Pharmaceutical and UCB adjust focus of collaboration

Otsuka Pharmaceutical files NDA in Japan

First study site chosen for pivotal phase II/III trial in hemophilia

Treatment begins in phase II study of Advaxis' ADXS-HPV

Spherix completes SPX-106 toxicology study for IND submission

Fifth Merrimack Pharmaceuticals program advances to clinic

World's first hepatitis E vaccine approved in China

Fostoin set for launch in Japan

Health Canada grants priority review status to Cinryze

Phytopharm reports preclinical data on Cogane in ALS

Astex Pharmaceuticals transfers results of epigenetics project to GSK

Nuron Biotech licenses flu vaccine to Mitsubishi Tanabe Pharma for Japan

Photocure completes enrollment in phase IIb trial of Visonac

Sobi signs licensing agreement for therapy for neonates with diuresis and seizures

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...